Management of heart failure

Medical Journal of Australia

Volumn 199, Issue 5, 2013, Pages 334-339

  Krum, Henry ^a   Driscoll, Andrea ^a  

^a MONASH UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

AMIODARONE; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; BRAIN NATRIURETIC PEPTIDE; CANDESARTAN; CARVEDILOL; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; EPLERENONE; ERYTHROPOIETIN; FERRIC CARBOXYMALTOSE; FISH OIL; HYDRALAZINE; IVABRADINE; METOPROLOL; NEBIVOLOL; NITRATE; SPIRONOLACTONE; VALSARTAN;

AMBULATORY CARE; ANEMIA; ARTICLE; CARDIAC RESYNCHRONIZATION THERAPY; DRUG CONTRAINDICATION; DRUG EFFECT; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; ELECTROCARDIOGRAPHY; HEART ARRHYTHMIA; HEART FAILURE; HUMAN; IMPLANTABLE CARDIOVERTER DEFIBRILLATOR; INTERDISCIPLINARY COMMUNICATION; IRON DEFICIENCY; LIFESTYLE MODIFICATION; MAXIMUM TOLERATED DOSE; NURSE PRACTITIONER; PATHOGENESIS; PATIENT REFERRAL; PRIMARY HEALTH CARE; PROTEIN BLOOD LEVEL; SYSTOLIC HEART FAILURE; TELEMONITORING; THORAX RADIOGRAPHY; TRANSTHORACIC ECHOCARDIOGRAPHY; TREATMENT FAILURE; UNSPECIFIED SIDE EFFECT;

ADRENERGIC BETA-ANTAGONISTS; ADULT; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CYCLIC NUCLEOTIDE-GATED CATION CHANNELS; DEATH, SUDDEN, CARDIAC; FEMALE; HEART FAILURE; HUMANS; MALE; MIDDLE AGED; MINERALOCORTICOID RECEPTOR ANTAGONISTS; MONITORING, PHYSIOLOGIC; PATIENT CARE TEAM; VENTRICULAR REMODELING;

EID: 84883477104     PISSN: 0025729X     EISSN: 13265377     Source Type: Journal    
DOI: 10.5694/mja12.10993     Document Type: Article

References (48)

1. National Heart Foundation of Australia and Cardiac Society of Australia and New Zealand. Guidelines for the prevention, detection and management of chronic heart failure in Australia. Updated October 2011. http://www.heartfoundation.org.au/SiteCollectionDocuments/Chronic_Heart_Failure_Guidelines_2011.pdf (accessed Aug 2013).
2. Hernandez AF, Hammill BG, Peterson ED, et al. Relationships between emerging measures of heart failure processes of care and clinical outcomes. Am Heart J 2010; 159: 406-413.
3. Krum H, Abraham WT. Heart failure. Lancet 2009; 373: 941-955.
4. Davie AP, Francis CM, Love MP, et al. Value of the electrocardiogram in identifying heart failure due to left ventricular systolic dysfunction. BMJ 1996; 312: 222.
5. Shuai XX, Chen YY, Lu YX, et al. Diagnosis of heart failure with preserved ejection fraction: which parameters and diagnostic strategies are more valuable? Eur J Heart Fail 2011; 13: 737-745.
6. Maisel AS, Krishnaswamy P, Nowak RM, et al; Breathing Not Properly Multinational Study Investigators. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med 2002; 347: 161-167.
7. Lam LL, Cameron PA, Schneider HG, et al. Meta-analysis: effect of B-type natriuretic peptide testing on clinical outcomes in patients with acute dyspnea in the emergency setting. Ann Intern Med 2010; 153: 728-735.
8. Johnston CI, Fabris B, Yoshida K. The cardiac renin-angiotensin system in heart failure. Am Heart J 1993; 126: 756-760.
9. Parati G, Esler M. The human sympathetic nervous system: its relevance in hypertension and heart failure. Eur Heart J 2012; 33: 1058-1066.
10. SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med 1992; 327: 685-691.
11. SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991; 325: 293-302.
12. Packer M, Bristow MR, Cohn JN, et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. US Carvedilol Heart Failure Study Group. N Engl J Med 1996; 334: 1349-1355.
13. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet 1999; 353: 9-13.
14. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 1999; 353: 2001-2007.
15. Packer M, Coats AJ, Fowler MB, et al; Carvedilol Prospective Randomized Cumulative Survival Study Group. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 2001; 344: 1651-1658.
16. Flather MD, Shibata MC, Coats AJ, et al; SENIORS Investigators. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J 2005; 26: 215-225.
17. Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999; 341: 709-717.
18. Pitt B, Remme W, Zannad F, et al; Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study Investigators. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003; 348: 1309-1321.
19. Zannad F, McMurray JJ, Krum H, et al; EMPHASIS-HF Study Group. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med 2011; 364: 11-21.
20. Cohn JN, Tognoni G; Valsartan Heart Failure Trial Investigators. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 2001; 345: 1667-1675.
21. Granger CB, McMurray JJ, Yusuf S, et al; CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. Lancet 2003; 362: 772-776.
22. McMurray JJ, Ostergren J, Swedberg K, et al; CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. Lancet 2003; 362: 767-771.
23. Dobre D, Haaijer-Ruskamp FM, Voors AA, van Veldhuisen DJ. beta-Adrenoceptor antagonists in elderly patients with heart failure: a critical review of their efficacy and tolerability. Drugs Aging 2007; 24: 1031-1044.
24. Richards AM. Mineralocorticoid receptor antagonists for heart failure. Expert Opin Pharmacother 2011; 12: 2801-2815.
25. Krum H, Cameron P. Diuretics in the treatment of heart failure: mainstay of therapy or potential hazard? J Card Fail 2006; 12: 333-335.
26. Rathore SS, Curtis JP, Wang Y, et al. Association of serum digoxin concentration and outcomes in patients with heart failure. JAMA 2003; 289: 871-878.
27. Cleland JG, Daubert JC, Erdmann E, et al; Cardiac Resynchronization-Heart Failure (CARE-HF) Study Investigators. The effect of cardiac resynchronization on morbidity and mortality in heart failure. N Engl J Med 2005; 352: 1539-1549.
28. Moss AJ, Hall WJ, Cannom DS, et al; MADIT-CRT Trial Investigators. Cardiac-resynchronization therapy for the prevention of heart-failure events. N Engl J Med 2009; 361: 1329-1338.
29. Tang AS, Wells GA, Talajic M, et al; Resynchronization-Defibrillation for Ambulatory Heart Failure Trial Investigators. Cardiac-resynchronization therapy for mild-to-moderate heart failure. N Engl J Med 2010; 363: 2385-2395.
30. Bardy GH, Lee KL, Mark DB, et al; Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT) Investigators. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med 2005; 352: 225-237.
31. Moss AJ, Zareba W, Hall WJ, et al; Multicenter Automatic Defibrillator Implantation Trial II Investigators. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med 2002; 346: 877-883.
32. Tavazzi L, Maggioni AP, Marchioli R, et al; Gissi-HF Investigators. Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet 2008; 372: 1223-1230.
33. Swedberg K, Komajda M, Böhm M, et al; SHIFT Investigators. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet 2010; 376: 875-885.
34. McMurray JJ, Anand IS, Diaz R, et al; RED-HF Committees and Investigators. Design of the Reduction of Events with Darbepoetin alfa in Heart Failure (RED-HF): a Phase III, anaemia correction, morbidity-mortality trial. Eur J Heart Fail 2009; 11: 795-801.
35. Anker SD, Comin Colet J, Filippatos G, et al; FAIR-HF Trial Investigators. Ferric carboxymaltose in patients with heart failure and iron deficiency. N Engl J Med 2009; 361: 2436-2448.
36. Jones RH, Velazquez EJ, Michler RE, et al; STICH Hypothesis 2 Investigators. N Engl J Med 2009; 360: 1705-1717.
37. Velazquez EJ, Lee KL, Deja MA, et al; STICH Investigators. Coronary-artery bypass surgery in patients with left ventricular dysfunction. N Engl J Med 2011; 364: 1607-1616.
38. McAlister FA, Stewart S, Ferrua S, McMurray JJ. Multidisciplinary strategies for the management of heart failure patients at high risk for admission: a systematic review of randomized trials. J Am Coll Cardiol 2004; 44: 810-819.
39. Driscoll A, Worrall-Carter L, Hare DL, et al. Evidence-based chronic heart failure management programs: reality or myth? BMJ Qual Saf 2011; 20: 31-37.
40. National Heart Foundation. Living well with chronic heart failure. Melbourne: NHF, 2008. http://www.heartfoundation.org.au/SiteCollectionDocuments/ Living%20well%20with%20chronic%20heart%20failure.pdf (accessed Jul 2013).
41. Phillips CO, Singa RM, Rubin HR, Jaarsma T. Complexity of program and clinical outcomes of heart failure disease management incorporating specialist nurse-led heart failure clinics. A meta-regression analysis. Eur J Heart Fail 2005; 7: 333-341.
42. Inglis SC, Clark RA, McAlister FA, et al. Which components of heart failure programmes are effective? A systematic review and meta-analysis of the outcomes of structured telephone support or telemonitoring as the primary component of chronic heart failure management in 8232 patients: Abridged Cochrane Review. Eur J Heart Fail 2011; 13: 1028-1040.
43. Sochalski J, Jaarsma T, Krumholz HM, et al. What works in chronic care management: the case of heart failure. Health Aff (Millwood) 2009; 28: 179-189.
44. Chaudhry SI, Phillips CO, Stewart SS, et al. Telemonitoring for patients with chronic heart failure: a systematic review. J Card Fail 2007; 13: 56-62.
45. Koehler F, Winkler S, Schieber M, et al; Telemedical Interventional Monitoring in Heart Failure Investigators. Impact of remote telemedical management on mortality and hospitalizations in ambulatory patients with chronic heart failure: the telemedical interventional monitoring in heart failure study. Circulation 2011; 123: 1873-1880.
46. Chaudhry SI, Mattera JA, Curtis JP, et al. Telemonitoring in patients with heart failure. N Engl J Med 2010; 363: 2301-2309.
47. Lee DS, Stukel TA, Austin PC, et al. Improved outcomes with early collaborative care of ambulatory heart failure patients discharged from the emergency department. Circulation 2010; 122: 1806-1814.
48. National Vascular Disease Prevention Alliance. Guidelines for the management of absolute cardiovascular disease risk. Melbourne: National Stroke Foundation, 2012. http://strokefoundation.com.au/site/media/AbsoluteCVD_ GL_webready.pdf (accessed Jul 2013).